ANI Pharma Inc (ANIP) 52.05 $ANIP Nexvet Biopharma

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 9:11 PM

ANI Pharma Inc (ANIP) 52.05 $ANIP

Nexvet Biopharma (NVET) Jumps: Stock Moves 9.2% Higher
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:25AM CDT
Nexvet Biopharma Public Limited Company (NVET) moved big last session, as its shares rose over 9% on the day.
ANIP: 52.05 (-1.64), NVET: 4.11 (-0.27)

Dimension Therapeutics (DMTX) Jumps: Stock Moves 6.7% Up
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:06AM CDT
Dimension Therapeutics, Inc. (DMTX) shares rose almost 7% in the last trading session.
ANIP: 52.05 (-1.64), DMTX: 10.15 (+0.08)

Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:34AM CDT
Pfizer (PFE) announced top-line results from the OPAL Beyond study on Xeljanz for the treatment of patients with active psoriatic arthritis.
ANIP: 52.05 (-1.64), PFE: 35.29 (-0.02), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)

Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 52.05 (-1.64), EXEL: 7.38 (+0.01)

Merck (MRK) Reveals Data from Ongoing Studies on Keytruda
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:46PM CDT
Merck (MRK) presented data on anti-PD-1 therapy, Keytruda at the annual meeting of the American Society of Clinical Oncology.
ANIP: 52.05 (-1.64), MRK: 56.81 (-0.37), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:52AM CDT
Pfizer (PFE) presented data from a phase Ib study on utomilumab for the treatment of advanced solid tumors.
ANIP: 52.05 (-1.64), MRK: 56.81 (-0.37), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 52.05 (-1.64), CLDX: 4.12 (-0.20), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)

Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 52.05 (-1.64), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)

Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), RTRX: 17.40 (-0.30), PBYI: 33.41 (-0.43)

Tobira Therapeutics (TBRA) in Focus: Stock Up 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:35AM CDT
Tobira Therapeutics, Inc. (TBRA) was a big mover last session, as the company saw its shares rise over 6% on the day.
ANIP: 52.05 (-1.64), TBRA: 10.06 (+0.36)

AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 12.87 (-0.13), ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), BMY: 72.65 (-0.08)

Amarin (AMRN) Looks Good: Stock Adds 6.7% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:40AM CDT
Amarin Corporation plc (AMRN) saw its shares rise almost 7% in the last trading session.
ANIP: 52.05 (-1.64), AMRN: 2.12 (-0.09)

Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)

AveXis (AVXS) Looks Good: Stock Adds 6.5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:40AM CDT
AveXis, Inc. (AVXS) saw its shares above 6% in the last trading session.
ANIP: 52.05 (-1.64), AVXS: 44.71 (-1.50)

Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 52.05 (-1.64), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08), NKTR: 15.80 (-0.48)

Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)

Teva's Huntington Disease Drug Receives CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:57AM CDT
Teva Pharmaceutical (TEVA) received a complete response letter from the FDA for SD-809 for the treatment of chorea associated with Huntington disease.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), TEVA: 53.01 (-0.30), BMY: 72.65 (-0.08)

Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 61.58 (-4.27), ANIP: 52.05 (-1.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Clarivate's Upcoming Conference Presentation: What to Expect

Conference Time: Will Clarivate Deliver the Goods? Grab your calendars, folks. November 18 is when Clarivate Plc is stepping into the spotlight at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference. Their bigwigs, Matti Shem Tov, the CEO, and Michael Easton, the CFO, will be there to spill the beans. They’re set to take the mike...

Pharmacy Credentials Gain Importance in Delaware Law

Credentialing Takes Front Seat in Pharmacy World Well, hold onto your hats because the pharmacy profession is getting a major upgrade, particularly if you're an investor watching healthcare regulation. The American Association of Colleges of Pharmacy (AACP) has thrown its support behind professional credentialing for pharmacists, which is a big deal, trust me. Pharmacy...

Clarivate's IPOne Revolutionizes AI for IP Pros

A New Dawn for IP Intelligence: Clarivate's Strategic Move Seems like Clarivate's out to shake things up in the IP world. Today, they've announced that their coveted patent and litigation intelligence is now seamlessly integrated with AI workflows on Claude through IPOne. For those not neck-deep in patents and trademarks every day, let’s break it down. This means IP...

Sivers Expands Reach via WT Microelectronics Deal

Breaking Ground with Strategic Collaborations Sivers Semiconductors is flexing its muscles in the semiconductor industry with a new strategic distribution agreement. They announced a partnership with WT Microelectronics, a company that's no rookie in the electronics distribution scene. With WT's global network covering a hefty 43 countries and a clientele of over 25,000,...

Florida's Insurance Premiums: Why They Keep Skyrocketing

What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...

Ladera Resort Snags Prestigious Design Honor in 2027

Recognition for a Unique Architectural Gem What's embedded in the heartbeat of Ladera Resort in St. Lucia? A crazy blend of stunning architecture right smack between the Pitons that makes it like nowhere else on Earth. And guess what? Ladera just snagged the Best Design award for 2027 at the Condé Nast Johansens Awards for Excellence. Winning this honor isn’t about...

2026 Shaw Prize: Celebrating Science's Global Impact

Shaw Prize: A Global Stage for Science When it comes to celebrating scientific breakthroughs, the Shaw Prize is the gold standard. On November 10th, 2026, the event unfolded at the iconic Hong Kong Convention and Exhibition Centre, and it was all about honoring those pushing the envelope in science. It’s year 23 for the Shaw Prize, and this ceremony didn’t just hand...

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

Iconic Brands Falter in New AI-Driven Consumer Landscape

Forget Recognition—It's All About Relevance Now Brand hearts are breaking, folks. That classic suite of household names just took a body blow from the Consequential Brand™ Test. Out of 73, a single champ emerged. Why? Because in the age where AI drives recommendations, it turns out recognizability ain't cutting it. This ain't your granddad’s customer loyalty game...